Pioneering cellular medicines for women’s health

We’re developing off-the-shelf cell therapies for high-impact women’s diseases, with lead programs in ovarian cancer, triple negative breast cancer and endometriosis.

Pioneering excellence in the field of immunotherapy

Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers, endometriosis and Alzheimer’s disease. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer and beyond.

Learn more about us

Some of our partners

Latest news

Cartherics to present at the CIMT Annual Meeting in Germany

By Christine Filippis / May 2, 2023
Cartherics is pleased to announce that PhD Candidate, Van To, will be presenting at the Association for Cancer Immunotherapy’s 20th...
Read More

Cartherics grants Shunxi Licence for CAR-T Cell Therapy for Ovarian Cancer in Greater China

By Christine Filippis / April 28, 2023
Melbourne, Australia, 28 April 2023 –  Cartherics Pty Ltd ("Cartherics"), a biotechnology company developing immune cell therapies for the treatment...
Read More

Cartherics’ offsite provides the opportunity to connect, engage and grow

By Christine Filippis / April 14, 2023
Cartherics recently held a company offsite at the RACV Healesville Country Club and Resort. Nestled in the beautiful Yarra Valley...
Read More